Haber R S, Rathan A, Weiser K R, Pritsker A, Itzkowitz S H, Bodian C, Slater G, Weiss A, Burstein D E
Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.
Cancer. 1998 Jul 1;83(1):34-40. doi: 10.1002/(sici)1097-0142(19980701)83:1<34::aid-cncr5>3.0.co;2-e.
Malignant cells exhibit increased glycolytic metabolism, and in many cases increased glucose transporter gene expression. The authors hypothesized that GLUT1 glucose transporter expression is increased in colorectal carcinoma, and that the degree of expression might have prognostic significance.
GLUT1 glucose transporter immunostaining was studied in normal colon and benign colon adenomas and in 112 colorectal carcinomas from patients for whom long term clinical outcome was known.
GLUT1 immunostaining was absent in normal colorectal epithelium and tubular adenomas, and absent or only weakly apparent in tubulovillous adenomas. The majority of carcinomas (101 of 112; 90%) had GLUT1 immunostaining. Tumors from 92 patients had low GLUT1 expression (< 50% of cells were GLUT1 positive) and 19 of these patients (21%) died of disease during follow-up. In contrast, tumors from 20 patients had high GLUT1 expression (> 50% of cells were GLUT1 positive) and 9 of these patients (45%) died of disease during follow-up. Disease specific mortality was greater in patients with high GLUT1 tumors (relative risk of 2.4; P=0.02). In a multivariate analysis to assess whether high GLUT1 staining correlated with increased mortality independently of Dukes stage, the risk of death from colon carcinoma in the group with high GLUT1 staining was 2.3 times that in the group with low GLUT1 staining, a difference that approached statistical significance (P=0.07).
GLUT1 glucose transporter expression is associated strongly with neoplastic progression in the colon, and assessment of the extent of GLUT1 immunostaining in colorectal carcinoma identifies patients with a poorer prognosis.
恶性细胞表现出糖酵解代谢增加，并且在许多情况下葡萄糖转运蛋白基因表达增加。作者推测，结直肠癌中葡萄糖转运蛋白1（GLUT1）的表达增加，且表达程度可能具有预后意义。
对正常结肠、良性结肠腺瘤以及112例已知长期临床结局患者的结直肠癌进行GLUT1葡萄糖转运蛋白免疫染色研究。
正常结直肠上皮和管状腺瘤中无GLUT1免疫染色，绒毛状管状腺瘤中无或仅微弱可见。大多数癌（112例中的101例；90%）有GLUT1免疫染色。92例患者的肿瘤GLUT1表达低（<50%的细胞GLUT1阳性），其中19例患者（21%）在随访期间死于疾病。相比之下，20例患者的肿瘤GLUT1表达高（>50%的细胞GLUT1阳性），其中9例患者（45%）在随访期间死于疾病。GLUT1高表达肿瘤患者的疾病特异性死亡率更高（相对风险为2.4；P=0.02）。在多变量分析中，为评估高GLUT1染色是否独立于Dukes分期与死亡率增加相关，GLUT1高染色组结肠癌死亡风险是GLUT1低染色组的2.3倍，该差异接近统计学意义（P=0.07）。
GLUT1葡萄糖转运蛋白表达与结肠肿瘤进展密切相关，评估结直肠癌中GLUT1免疫染色程度可识别预后较差的患者。
